搜索
Vir Biotechnology Inc
VIR添加自选
8.790USD
-0.300-3.30%
收盘 05/15, 16:00（美东）报价延迟15分钟
1.53B总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-3.30%
5天
-3.62%
1月
-15.97%
6月
+56.13%
今年开始到现在
+45.77%
1年
+93.19%
TradingKey Vir Biotechnology Inc股票评分
单位: USD 更新时间: 2026-05-15操作建议
Vir Biotechnology Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名23/382位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价20.50。中期看，股价处于上升通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Vir Biotechnology Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Vir Biotechnology Inc亮点
亮点风险
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.
业绩增长期
公司处于发展阶段，最新年度总收入68.56M美元
估值低估
公司最新PE估值-2.80，处于3年历史低位
机构加仓
最新机构持股130.35M股，环比增加6.85%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值948.00
活跃度降低
近期活跃度降低，过去20天平均换手率-0.06
分析师目标
根据
10
位分析师
买入
评级
20.500
目标均价
+119.72%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Vir Biotechnology Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Vir Biotechnology Inc简介
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.
公司代码VIR
公司Vir Biotechnology Inc
CEODe Backer (Marianne)
网址https://www.vir.bio/
相关品种
